Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's Proprietary Linker Technology

Contributed by: PR Newswire

Tags

Mycenax-RIN-ADC

More Like This

Mycenax and SPERA PHARMA Forge Strategic Alliance to Streamline ADC Drug Substance and Drug Product Manufacturing Services

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family